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Abstract
Background: Idiopathic intracranial hypertension (IIH) is a condition with few effective management options. So far, there
have been no randomized controlled trials evaluating new treatments in IIH.
Objectives: The purpose of this paper is to outline the trial design for the Idiopathic Intracranial Hypertension Drug Trial
(IIH:DT), assessing an innovative medical treatment in IIH and the rationale for the chosen trial methodology.
Methods: IIH:DT is a phase II double-blind randomized placebo-controlled trial recruiting 30 female participants with active
IIH (intracranial pressure >25cm H2 O and papilledema). Participants are randomized in a 1:1 ratio to 12 weeks of either AZD4017,
an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, or a matching placebo. They receive either 400 mg of AZD4017 or placebo
twice daily. Participants are followed up at Weeks 1, 2, 3, 4, 6, 8, 10, 12, and 16 postrandomization. The primary outcome is to
examine the effect of AZD4017 on intracranial pressure, measured by lumbar puncture, over 12 weeks. Secondary outcome
measures include IIH symptoms, visual function, papilledema, headache measures, safety, and tolerability. Cerebrospinal fluid,
serum, plasma, urine, and adipose tissue are also taken for exploratory outcomes.
Results: All participants were recruited between April 2014 and August 2016.
Conclusions: IIH:DT is the first phase II double-blind randomized placebo-controlled trial assessing the efficacy and safety of
the novel pharmacological intervention, AZD4017, for the treatment of IIH.
Trial Registration: Clinicaltrials.gov NCT02017444; https://clinicaltrials.gov/ct2/show/NCT02017444 (Archived by WebCite
at http://www.webcitation.org/6tVHesN6s)
(JMIR Res Protoc 2017;6(9):e181)   doi:10.2196/resprot.7806
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Introduction
Idiopathic intracranial hypertension (IIH), also known as benign
intracranial hypertension or pseudotumor cerebri, is a condition
of unknown etiology characterized by elevated intracranial
pressure (ICP) and papilledema. IIH typically affects young
obese females of child-bearing age, causing disabling daily
headaches and visual loss. Among this population, the incidence
of IIH is 12-20 per 100,000 [1,2] (0.5-2 per 100,000 in the
general population [3,4]). In line with the global obesity
epidemic, the incidence of IIH is expected to rise and
consequently contribute to significant morbidity in young obese
females.
A 2015 Cochrane review identified two randomized controlled
trials (RCTs) assessing the use of acetazolamide in IIH [5]. The
review included the Idiopathic Intracranial Hypertension
Treatment Trial (IIHTT), which demonstrated beneficial effects
of acetazolamide in IIH patients with mild visual loss [6], and
a UK pilot study of acetazolamide [7]. Previous studies have
highlighted elevated attrition rates [5] possibly due to drug side
effects, which include paresthesia and gastrointestinal symptoms.
The Cochrane review concluded that there was insufficient
evidence to support the use of acetazolamide and that further
well-designed RCTs are required [5].
For progressive or acute deterioration of vision in IIH, surgical
techniques such as cerebrospinal fluid (CSF) shunting, optic
nerve sheath fenestration, or venous sinus stenting have been
used to prevent blindness. However, there is limited evidence
to support these surgical interventions.
A 2010 prospective cohort study evaluated the effect of a
low-calorie diet to promote weight loss in the treatment of IIH.
The resulting dietary weight loss led to improvements in ICP,
headaches, and vision [8]. Although weight loss is generally
advised, the management of IIH varies considerably owing to
a lack of supporting evidence [9,10]. Meaningful and sustained
weight loss is also difficult to achieve. Consequently, alternative
approaches are needed.
In the first phase II RCT in IIH ever conducted, the Idiopathic
Intracranial Hypertension Drug Trial (IIH:DT) will assess
whether the 11β-hydroxysteroid dehydrogenase type 1
(11β-HSD1) inhibitor AZD4017 is a safe and effective treatment
for IIH.
Scientific Background
The intracellular enzyme 11β-HSD1 converts inactive cortisone
to active cortisol, amplifying local glucocorticoid availability
independent of systemic circulating cortisol. AZD4017 is an
oral selective, competitive inhibitor of 11β-HSD1 originally
developed as a potential treatment for diabetes mellitus type 2,
obesity, and metabolic syndrome.
Glucocorticoid metabolism has previously been characterized
in IIH subjects before and after therapeutic weight reduction
(loss of 15.7 kg [SD 8.0] of body weight) [8]. Global 11β-HSD1
activity decreased with weight loss as assessed by the urinary
THF+allo-THF:THE ratio measured by gas
chromatography/mass spectroscopy. Importantly, there was a
relationship between the therapeutic reduction in ICP and the
decrease in global 11β-HSD1 activity (r=.504, P=.03) [11].
These data not only highlight the potential link between
11β-HSD1 activity and ICP but offer the opportunity to test our
hypothesis that specific inhibition of 11β-HSD1 will decrease
ICP in IIH participants, opening an entirely novel therapeutic
avenue.
Disordered CSF dynamics have been suspected of causing the
raised ICP seen in IIH. The choroid plexus is the principle
contributor to CSF production, which is ultimately driven by
the sodium potassium ATPase (Na+K+ATPase) pump. Sodium
transport creates an osmotic gradient driving water into the CSF
[12]. Increasing the level of fluid within a closed system in turn
increases ICP.
Aqueous humor produced by the ocular ciliary epithelium in
the eye occurs by a mechanism analogous to CSF secretion in
the choroid plexus, an embryologically related tissue [13]. A
nonselective 11β-HSD inhibitor, carbenoxolone, was assessed
in lowering ocular hypertension over 4 days of treatment,
demonstrating a 10% (mean pressure: baseline 22.7, treatment
20.5, placebo 21.6; P˂.001) reduction in intraocular pressure
compared to placebo. Inhibition of intracellular cortisol
conversion within the ocular ciliary epithelium led to a decrease
in sodium transport and a reduction in the osmotic gradient. As
a consequence, water movement into the aqueous humor also
decreased [14]. A similar process may occur at the choroid
plexus with CSF secretion.
Safety Considerations
AZD4017 is a fully reversible, competitive inhibitor of
11β-HSD1. It has been tested in two animal models: rats and
nonhuman primates. The drug was found to be an effective
inhibitor of 11β-HSD1 in human and nonhuman primates but
a poor inhibitor in other animals [15]. AZD4017 was also tested
in five phase I and II human clinical trials assessing the drug in
healthy males, obesity, diabetes mellitus type 2, and raised
intraocular pressure. The following safety considerations were
found.
Liver
In animal models, reversible hypertrophy of the liver was
observed in rats, which was adaptive rather than degenerative.
However, nothing was noted in the cynomolgus monkey.
Elevated transaminases, without concomitant rise in bilirubin,
were observed in a few human subjects treated with AZD4017
in the multiple-ascending dose study. The findings were
reversible on drug discontinuation, and no subjects were
clinically symptomatic [15].
We hypothesize that specific inhibition of 11β-HSD1 will
decrease ICP and consequently improve the symptoms and signs
of IIH, providing a new pharmacological treatment for IIH.
Hypothalamic-Pituitary Axis
There were adrenal changes in the animal models, but these
were considered adaptive rather than adverse. In the clinical
studies, increases in adrenocorticotropin and
dehydroepiandosterone- sulphate were seen, indicating an
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activation of the hypothalamic, pituitary, adrenal (HPA) axis.
However, serum cortisol and testosterone levels were
unchanged. There was no sign of adrenal insufficiency detected
in humans [15].
Thyroid
Adaptive thyroid changes were seen in rats. In humans, there
was no difference in thyroid hormones between AZD4017 and
placebo-treated subjects. Despite this, thyroid function will be
monitored owing to the preclinical results [15].
Trial Objectives
The purpose of this paper is to outline the design considerations
for IIH:DT. The aims of the trial are to assess the efficacy,
safety, and tolerability of the selective 11β-HSD1 inhibitor
AZD4017 for the treatment of IIH.
Methods
Trial Design
IIH:DT is a multicenter phase II double-blind randomized,
placebo-controlled trial in the United Kingdom comparing 12
weeks of treatment with 400 mg AZD4017 twice daily with a
matching placebo in 30 female participants with active IIH
(intracranial pressure [ICP] >25cm H2 O and papilledema).
Participants are followed up for 16 weeks. The primary outcome
examines the effect of AZD4017 on ICP, measured by lumbar
puncture (LP), over 12 weeks (see Figure 1). An initial
prescreening includes papilledema assessment and a blood test.
Potential participants are invited to a screening 7-30 days later
where an LP is performed. If eligible, random allocation to
either AZD4017 or placebo occurs. Following 12 weeks of
treatment, a repeat LP is performed. A final follow-up visit is
then attended at Week 16.
Recruitment
The aim of the trial was to recruit 30 participants (see sample
size below) from four National Health Service (NHS) trusts
across the United Kingdom between April 2014 and August
2016. Patient lists are screened before ophthalmology and
research clinics, and those meeting the basic eligibility criteria
approached at their appointment to determine their interest in
trial participation. Consent is taken from willing patients to
undertake prescreening. Prescreening consists of slit lamp
examination for papilledema (Frisen grading ≥1) and a blood
test to determine initial eligibility (see Table 1). If they continue
to meet the eligibility criteria, they are asked to complete a 7-day
headache diary (see Multimedia Appendix 1) and provide a
24-hour urine sample for glucocorticoid metabolite analysis.
Participants are asked to return for a screening visit at least 7
days after their prescreening visit (see Trial Visits for further
information).
Eligibility
Patients are recruited based on the presence of active IIH, either
newly diagnosed or a long-standing diagnosis, with any degree
of visual loss and fulfillment of the trial inclusion and exclusion
criteria (Table 1; [16]). As IIH predominantly affects obese
females of child-bearing age, this will be the focus of the trial.
Males and children tend to present differently with atypical
features and may have an alternative pathogenesis [17] and so
are excluded.
During the trial, the HPA hormones are monitored. We have
excluded those on glucocorticoid and other hormonal
medications as this may confound monitoring of the HPA axis.
Those on mild topical steroid preparations or on inhaled steroids
for asthma have been included as the systemic levels are low.
The inclusion of IIH patients on acetazolamide and other
diuretics is permitted if the participant is on a stable dose.
Figure 1. IIH:DT trial design.
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Table 1. Inclusion and exclusion criteria for IIH:DT.
DescriptionCriteria
Provision of informed consent prior to any study specific proceduresInclusion
Female patients 18-55 years
Diagnosis of IIH by the Modified Dandy criteria [16] with active disease (papilledema [Frisen grade ≥1] and significantly raised
ICP>25cm H2 O) and normal brain imaging during previous routine diagnostic work-up (evaluated by either magnetic resonance
venography or computed tomography with venography)
Participants must be willing to use one form of highly effective nonhormonal contraception. Participants must agree to undergo a urine
pregnancy test at screening and at monthly intervals until the final follow-up visit 4 weeks after discontinuation of study treatment.
Participants are able to continue other medications to treat their IIH (eg, acetazolamide, diuretics) but this dose should remain fixed
throughout the study. Acetazolamide may be taken but the participant must be on a stable dose.
Must be able to understand the consent form and comply with study requirements
Optic nerve sheath fenestration (as distortion of the optic nerve may prevent accurate assessment of their disease state). Participants
who have had previous failed CSF shunting will be eligible for enrollment if they fulfill all other enrollment criteria.
Exclusion
Abnormal neurological examination (aside from papilledema and consequent visual loss or VI nerve palsy)
Unable to perform a visual field reliably
Positive urine dipstick pregnancy test or planning to conceive in the 4 study months.
Have estimated Glomerular Filtration Rate calculated by Modification of Diet in Renal Disease equation of <60ml/min/1.73m2
Have any endocrine disorder, eg, thyroid dysfunction. Those with polycystic ovary syndrome will be included in the trial as there is
a known association with IIH. Diabetes will not exclude participants.
Suspicion of or known Gilbert’s disease
Creatine kinase >2x upper limit of normal on 2 consecutive measurements
Alanine transaminase and/or aspartate transaminase >2x upper limit of normal
Alkaline phosphatase >upper limit of normal
Bilirubin (total) >2x upper limit of normal
Must not have donated blood within 2 months of screening and avoid further donation for 4 months following the study
Participant is, at the time of signing the informed consent, a user of recreational or illicit drugs (including marijuana) or has had a recent
history (within the last year) of drug or alcohol abuse or dependence, in the opinion of the investigator
Pregnant or breastfeeding mother, unless willing to discontinue breastfeeding by baseline visit
Have uncontrolled systemic hypertension (blood pressure >160 systolic on 3 successive measurements on the screening visit
Are receiving systemic (including vaginal/rectal) glucocorticoid treatment at the time of the screening visit
Are taking any hormone-based medication, including hormone contraceptives (but not including intrauterine system/hormonal coil),
at the time of screening
Are taking probenecid at the time of screening visit
Have any screening laboratory abnormality that, in the investigator’s judgement, is considered to be clinically significant or any
screening laboratory value that is outside the sponsor-specified ranges at screening; testing may be repeated once to see if the value
returns to within the range, but any laboratory abnormality must be resolved prior to the baseline visit
History of any clinically significant disease or disorder that, in the opinion of the investigator, may either put the subject at risk because
of participation in the study or influence the results or the subject’s ability to participate in the study. Specifically, a diagnosis of any
inflammatory disorder that might reasonably need treatment with glucocorticoids during the course of the study should be considered
for exclusion.
History or presence of significant gastrointestinal, hepatica, or renal disease or any other condition known to interfere with absorption,
distribution, metabolism, or excretion of drugs
Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of the Investigational
Medicinal Produce as judged by the investigator
Have been involved in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study sites)
Have participated in any other interventional studies within 1 month prior to the screening visit. Participation in the IIH national
database or other observational studies will not prevent enrollment to this study.
Previous randomization for treatment in this study
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aA history of steatosis will not be considered an exclusion criterion.
Ethics, Regulatory Approvals, and Dissemination
The trial will be conducted in accordance with the Research
Governance Framework for Health and Social Care, the
applicable UK Statutory Instruments (which include the
Medicines for Human Use Clinical Trials 2004 and subsequent
amendments), the Data Protection Act 1998, Human Tissue Act
2008, Human Tissue (Scotland) Act 2006, and Guidelines for
Good Clinical Practice.
This trial will be carried out under a Clinical Trial Authorization
(CTA) in accordance with the Medicines for Human Use
Clinical Trials regulations. IIH:DT was approved by the National
Research Ethics Committee York and Humber–Leeds West on
November 19, 2013 (13/YH/0366), and received CTA for the
use of investigational medicinal product on January 21, 2014.
IIH:DT is sponsored by the University of Birmingham (RG
13-022). IIH:DT is registered on clinicaltrials.gov
(NCT02017444) and the European Clinical Trials Database
(EudraCT Number: 2013-003643-31.)
Results will be disseminated through internal reports, relevant
conferences, peer-reviewed scientific journals, and online
publications. No personally identifiable data will be published.
Participants and general practitioners will be informed of results
through a summary scientific report available through the trial
website.
Trial Drug and Placebo
The dose to be used in this trial is 400 mg taken as two 200 mg
tablets, twice daily. Doses are taken 12 hours apart, typically
around 7 a.m. and 7 p.m. each day. Participants take the trial
medication for 12 weeks.
AZD4017 has been well tolerated in previous phase I and II
studies. The largest single dose used has been 1200 mg for 9
days and the longest duration of use has been 28 days at 400
mg twice daily [15]. A 12-week treatment period is considered
sufficient to see sustained inhibition of 11β-HSD1 by AZD4017
and potentially changes in ICP. This duration is longer than
previous treatment with AZD4017; therefore, safety as well as
drug efficacy is a key outcome.
AZD4017 is compared to placebo rather than a current treatment
of IIH. During trial design and registration, there was no
evidence supporting the use of any particular medical treatment
for IIH [18]. While IIH:DT has been recruiting, new evidence
emerged demonstrating the efficacy of acetazolamide in IIH
patients with mild visual loss [6]. However, a recent systematic
review suggested the evidence was inconclusive [5]. In addition,
the IIH patient cohort included in this trial will include moderate
to severe visual deficits. For these reasons, a placebo is still
considered the optimal comparator for this trial.
Discontinuation of the trial drug can occur for a number of
reasons: a clinically significant serious adverse event,
deterioration in their IIH requiring CSF diversion surgery, severe
noncompliance, hepatotoxicity, and muscle toxicity.
In the situation of very raised liver enzymes—alanine
transaminase and/or aspartate transaminase >5 times the upper
limit of normal (ULN) and/or bilirubin >2 times ULN and/or
Hy’s Law criteria met—any time after randomization, the
underlying cause for the liver enzyme elevation will be
evaluated. If there is no improvement after 7 days or if the liver
enzyme abnormality continues to worsen, depending on the
clinical severity, then the treatment will be stopped. Subjects
will also discontinue the trial drug if they fulfill all of Hy’s Law
criteria for 2 weeks. The trial will be stopped completely if more
than one Hy’s Law case persists for 2 weeks or more than three
subjects (10%) meet the liver stopping criteria, unless another
cause of liver enzyme abnormality is identified in these subjects.
Randomization
Randomization has been performed by the contract
manufacturing organization (Almac) supplying and coding the
trial medication on behalf of AstraZeneca. Block randomization
was used so that each block of trial numbers contains a random
assignment of equal numbers of active and placebo treatment
allocations.
Drug allocation takes place if the participant is confirmed to be
eligible at the end of the screening visit and consents to enter
the trial. The next available trial number is given to the
participant in order. A drug pack, containing either AZD4017
or placebo, is identified by the designated trial number and will
be provided to the patient on a monthly basis during the 12-week
treatment period.
Sample Size
We aimed to recruit 30 participants to allow for a sample size
of 24 participants (12 per arm), with a 20% allowance for
dropouts, which would allow 90% power (alpha=.05) to detect
a difference of 14% in ICP (assuming a standard deviation of
10% for ICP).
Outcomes
Primary Outcome
The primary outcome examines the effect of AZD4017 on ICP
from baseline to 12 weeks postrandomization. ICP was chosen
as the primary outcome to reflect the hypothesized action of
AZD4017 inhibition of 11β-HSD1 with consequent reduction
in CSF secretion and ICP.
Secondary Outcomes
Raised ICP underlies the symptoms and signs of IIH, thus
alterations in ICP should result in clinical fluctuations. The
following secondary outcomes are recorded:
• IIH symptoms (presence or absence of tinnitus, visual loss,
diplopia, visual obscurations, and headache)
• IIH visual function in both eyes (measured by log of the
minimum angle of resolution charts to assess visual acuity,
automated perimetry [Humphrey 24-2 central threshold] to
measure the visual field mean deviation and MARs charts
to evaluate contrast sensitivity)
• papilledema is evaluated using spectral domain optical
coherence tomography (Spectralis, Heidelberg Engineering)
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and fundal photographs with Frisen classification (by
masked neuro-ophthalmologists) to grade the images
• headache-associated disability through the headache impact
test-6 score (HIT 6), headache severity, frequency, and the
use of analgesia (days/weeks)
• anthropological measures (blood pressure, body mass index,
waist/hip ratio)
• safety and tolerability profile of AZD4017 through adverse
event reporting and safety bloods (see Table 2)
Exploratory Outcomes
Exploratory studies evaluate the ability of AZD4017 to inhibit
11β-HSD1 in IIH patients through evaluation of:
• hepatic 11β-HSD1 activity by prednisone administration
to measure prednisolone levels over 4 hours
• global 11β-HSD1 activity through urinary glucocorticoid
metabolites
• 11β-HSD1 activity in subcutaneous adipose tissue following
cortisone incubation ex vivo
• plasma and CSF drug levels and pharmacokinetic analysis
• cortisone and cortisol in serum and CSF
In addition, dual-energy x-ray absorptiometry (DXA) scanning
is used to assess body habitus.
Trial Visits
Screening
A screening visit is attended between 7 and 30 days after
successful prescreening. Participants are then assessed over 1
day or a split visit (see Figure 2). Following informed consent,
a general history and examination as well as a neurological
assessment is performed. A urinary pregnancy test and blood
samples are taken followed by visual tests, DXA scanning, an
LP, and fat biopsy. If the participant is eligible following
screening, the data collected will be used as baseline data.
Table 2. A timeline of study visits and the outcome tests performed at each visit. Safety bloods include renal function (urea, creatinine, and electrolytes),
liver function (aspartate transaminase, alanine transferase, bilirubin, albumin, alkaline phosphatase, gamma-glutamyl transferase), thyroid function
(thyroid stimulating hormone free thyroxine), and creatine kinase.
WeeksMeasureOutcome
1612108643210
Primary outcome
XXLumbar punctureICP
Secondary outcomes
XXXBody mass index, blood pressure, waist/hip, body compositionAnthropometric measures
XXXPulsatile tinnitus, visual loss, diplopia, visual obscurationsIIH symptoms
XXXVisual acuity, contrast sensitivityVisual function
XXXHumphrey visual field (24-2)
XXXOptical coherence tomographyPapilledema
XXXRetinal photographs
XXXHIT-6, headache index, analgesia useHeadache
XXXXXXXXXXHistory, +/- examination, complianceMedical assessment
XXXXXXSafety bloods
XXXXXXPregnancy test
Exploratory outcomes
XXXXXX24-hour urineGlobal 11β-HSD1 activity
XXPrednisone to prednisolone measurements in serumHepatic 11β-HSD1 activity
XXSubcutaneous adipose biopsyAdipose 11β-HSD1 activity
XXDXABody habitus
XXXPlasma and CSFPharmacokinetic analysis
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Figure 2. Overview of the screening visit.
Subsequent Visits
The treatment period is 12 weeks. Participants will be assessed
at 1, 2, 3, 4, 6, 8, 10, 12, and 16 weeks (see Table 2). All visits
will determine adverse events and treatment compliance. Visits
1, 4, 8, 12, and 16 will require safety and hormone bloods as
well as a urinary pregnancy test. The 12-week visit will repeat
the screening visit. Following 4 weeks off the trial drug, patients
will be assessed at 16 weeks for visual tests, headaches, bloods,
IIH symptoms, and adverse events. The follow-up visit at Week
16 is deemed sufficient time for the effects of the trial drug to
have dissipated. Any relapses in IIH-related symptoms are then
determined.
Statistical Methods
The primary analysis of efficacy is based on the full analysis
set, as defined by ICH guidance document E9: Statistical
Principles for Clinical Trials. This analysis adheres as closely
as possible to the intention-to-treat ideal and is based on data
from all randomized participants with participants analyzed in
the treatment group to which they were randomized.
Primary and Secondary Outcome Analyses
The primary comparison groups are composed of those
randomized to AZD4017 versus placebo. For all major outcome
measures, summary statistics and differences between groups
(eg, mean differences) will be presented with 95% confidence
intervals and P values from two-sided tests. No adjustment for
multiple comparisons will be made.
The primary outcome examines the effect of AZD4017 on ICP
from baseline to 12 weeks postrandomization. Data will be
reported with means and standard deviations or medians and
ranges for nonparametric data. The ICP at 12 weeks for the two
trial arms will be compared using a linear regression model with
baseline ICP included as a covariate in the model.
Secondary outcome measures are analyzed at 12 and 16 weeks.
The majority of secondary outcomes are continuous data items,
which will be analyzed as per the primary outcome. For the
visual function data that are collected in both eyes, it is expected
that the participant’s data will be correlated, so the primary
analyses will use data from both eyes and will be analyzed using
a linear mixed model, with participants included as a random
effect. The visual function data for each eye will also be
analyzed separately as per the primary outcome, but this will
be a secondary analysis. The IIH symptom data is binary and
will be analyzed using log-binomial models with baseline
symptom included in the model as a covariate.
Study Withdrawal
Participants are free to withdraw from the study at any time.
Such participants will always be asked about the reason(s) and
the presence of any adverse events. If the participant is
withdrawn from the trial by the investigator for any reason at
any visit during the study, assessments for the early
discontinuation visit will be completed during that visit, and
the withdrawn participant asked to return for Visit 12 between
83 and 97 days, inclusive.
If the participant needs to be withdrawn from the active
treatment phase between trial visits for safety reasons, trial
medication will be stopped immediately and the participant will
be instructed to attend the next arranged clinic visit, which will
be treated as an early discontinuation visit. If it is considered
appropriate by the investigator, more frequent or additional
follow-up visits can be scheduled (if willing, the participant
will be asked to attend the 12-week final trial visit). Withdrawn
participants will not be replaced.
JMIR Res Protoc 2017 | vol. 6 | iss. 9 | e181 | p.7http://www.researchprotocols.org/2017/9/e181/
(page number not for citation purposes)
Markey et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Monitoring
Adverse Event Reporting
All serious adverse events (SAEs) must be reported, whether
or not considered causally related to the trial drug or to study
procedures. A clinician must assess the severity, causality, and
expectedness of the SAE. If the event is considered to be related
to the study drug, then the SAE will be classed as a serious
adverse reaction (SAR). If the SAR is listed in the safety
information of AZD4017, then it is listed as expected and
included in the ongoing safety review of the study. If it is not
an expected SAR for AZD4017, then it is listed as a suspected
unexpected serious adverse reaction (SUSAR). The trial team
will then be contacted to unblind the subject’s medication
allocation. A fatal or life-threatening SUSAR will be reported
to the Medicines and Healthcare Products Regulatory Agency
and the research ethics committee within 7 days.
Unblinding
Investigators and subjects are unaware whether the product is
AZD4017 or placebo (double-blinded); this information is held
by local pharmacies in the form of scratchcards detailing the
trial number and a scratch-off panel. Unblinding can take place
in the case of a SUSAR and in medical emergencies, when
knowing the treatment will change the management of the
patient.
Monitoring Committees
A trial steering committee made up of independent members
(including the chair) and trial team members provides oversight
of the trial. An independent data monitoring committee (DMC)
monitors unblinded efficacy and safety reports. If there are any
major safety concerns, the DMC can recommend early
discontinuation of the trial.
Results
The trial opened March 2014 with the first patient recruited
April 2014. Additional sites were opened at the Walton Centre,
Liverpool (January 2016), Southern General Hospital, Glasgow
(March 2016), and Royal Hallamshire Hospital, Sheffield (April
2016) to facilitate recruitment. The DMC and trial steering
committee meet regularly to monitor the course of the IIH:DT.
The trial results are expected in September 2017.
Discussion
Principal Considerations
Recruitment to IIH:DT was completed in August 2016. Results
from the trial are still awaited. The two RCTs evaluating IIH
treatments completed thus far have investigated an established
drug, acetazolamide. IIH:DT is the first to assess the efficacy
of a new drug treatment, an 11β-HSD1 inhibitor (AZD4017),
not tested in IIH before. More importantly, it aims to establish
the safety profile of AZD4017 in IIH. Safety monitoring
involves regular safety bloods and adverse event recording.
These are performed in accordance with prior AZD4017 study
results. This is the longest period of time the drug has been
administered to humans. Positive safety results will provide
important information for future trials using AZD4017.
Conclusions
IIH is in need of new treatments. IIH:DT is the first phase II
double-blinded randomized placebo-controlled trial in IIH. It
assesses a novel therapeutic pathway through inhibition of
11β-HSD1 by the drug AZD4017. In addition to the primary
outcome of ICP, a range of secondary outcomes including visual
function, headache, and papilledema will be assessed. IIH:DT
aims to establish initial evidence of efficacy and safety that
could lead to a future large phase III study using AZD4017 in
IIH.
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